11-24-2016

**Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients**

Josh Levitsky

Elizabeth C. Verna

Jacqueline G. O’Leary

Natalie H. Bzowej

D Moonka

_Henry Ford Health System, DMOONKA1@hfhs.org_

*See next page for additional authors*

Follow this and additional works at: [https://scholarlycommons.henryford.com/gastroenterology_articles](https://scholarlycommons.henryford.com/gastroenterology_articles)

**Recommended Citation**


This Article is brought to you for free and open access by the Gastroenterology at Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Gastroenterology Articles by an authorized administrator of Henry Ford Health System Scholarly Commons.
nonindustry-funded studies (45% and 41%, respectively; \( P = 0.88 \) by chi-square test).

In randomized, controlled trials in critical care medicine that were published in the ICMJE journals with the highest impact factor, a substantial proportion of trials do not produce secondary publications. Because established trial groups are more likely to publish secondary analyses than independent groups, this difference may represent a missed opportunity in advancing scientific discovery and hypothesis generation that could be addressed through responsible data sharing. There appears to be a considerable delay between the publication of original and secondary analyses. We submit that these observations be taken into consideration in developing guidelines for data sharing to maximize opportunities and benefits for primary and secondary investigators. (Our database will be made available 6 months after the publication of this letter.)

Mahesh Ramanan, F.C.I.C.M.
Redcliffe Hospital
Brisbane, QLD, Australia

John Myburgh, Ph.D., F.C.I.C.M.
George Institute for Global Health
Sydney, NSW, Australia

Balasubramanian Venkatesh, M.D., F.C.I.C.M.
University of Queensland
Brisbane, QLD, Australia

bmvenkat@bigpond.net.au

and Others

A complete list of authors is available with the full text of this letter at NEJM.org.

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.


DOI: 10.1056/NEJMc1610367

Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant Recipients

TO THE EDITOR: Hepatitis C virus (HCV) infection continues to be the most frequent indication for liver transplantation, but recurrence of infection is nearly universal in patients who are viremic at the time of transplantation.1 Direct-acting antiviral agents (DAAs) have been shown to be effective in treating recurrent HCV infection2,3 but have not been tested in preventing reinfection at the time of liver transplantation. Because HCV RNA levels fall precipitously after liver transplantation owing to removal of the liver, the immediate perioperative period before rebound of viremia represents a unique opportunity to cure HCV infection.4 We hypothesized that a DAA regimen shorter than the standard 12 to 24 weeks starting immediately before the transplantation might prevent reinfection of the new graft.

We conducted an open-label, multicenter, phase 2 study (ClinicalTrials.gov number, NCT02350569) involving wait-listed patients with chronic HCV genotype 1 infection who were undergoing a first liver transplantation from an HCV-negative donor. Patients who had received previous DAA treatment or who had a creatinine clearance of less than 40 ml per minute at the time of transplantation were excluded. A total of 37 patients were screened, and 16 with a median unadjusted Model for End-Stage Liver Disease score of 13 (on a scale from 6 to 40, with higher scores indicating more advanced liver disease) were enrolled (Fig. S1 and Table S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Patients received a single dose of ledipasvir (90 mg)–sofosbuvir (400 mg) the day they arrived at the hospital for transplantation and once daily for 4 weeks postoperatively. The primary efficacy end point was a sustained virologic response 12 weeks after the end of the 4-week treatment. Deep sequencing of HCV NS5A

Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant Recipients

TO THE EDITOR: Hepatitis C virus (HCV) infection continues to be the most frequent indication for liver transplantation, but recurrence of infection is nearly universal in patients who are viremic at the time of transplantation.1 Direct-acting antiviral agents (DAAs) have been shown to be effective in treating recurrent HCV infection2,3 but have not been tested in preventing reinfection at the time of liver transplantation. Because HCV RNA levels fall precipitously after liver transplantation owing to removal of the liver, the immediate perioperative period before rebound of viremia represents a unique opportunity to cure HCV infection.4 We hypothesized that a DAA regimen shorter than the standard 12 to 24 weeks starting immediately before the transplantation might prevent reinfection of the new graft.

We conducted an open-label, multicenter, phase 2 study (ClinicalTrials.gov number, NCT02350569) involving wait-listed patients with chronic HCV genotype 1 infection who were undergoing a first liver transplantation from an HCV-negative donor. Patients who had received previous DAA treatment or who had a creatinine clearance of less than 40 ml per minute at the time of transplantation were excluded. A total of 37 patients were screened, and 16 with a median unadjusted Model for End-Stage Liver Disease score of 13 (on a scale from 6 to 40, with higher scores indicating more advanced liver disease) were enrolled (Fig. S1 and Table S1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Patients received a single dose of ledipasvir (90 mg)–sofosbuvir (400 mg) the day they arrived at the hospital for transplantation and once daily for 4 weeks postoperatively. The primary efficacy end point was a sustained virologic response 12 weeks after the end of the 4-week treatment. Deep sequencing of HCV NS5A
Correspondence

and NS5B was performed for all recipients at baseline.

Figure 1 shows HCV RNA levels from day –1 to the end of study. The rate of sustained virologic response for the 4-week course was 88% (Table S2 in the Supplementary Appendix). One patient had a relapse after the 4 weeks, but a sustained virologic response was achieved after retreatment with 12 weeks of ledipasvir–sofosbuvir per the study protocol, leading to an overall cure in 15 of the 16 patients (94%). This patient had three NS5A resistance-associated substitutions at study enrollment. One patient discontinued treatment after the creatinine clearance fell below a predefined threshold of 30 ml per minute on day 5. Overall, 88% of the patients had adverse events after liver transplantation, and 31% had serious adverse events (Tables S3 and S4 in the Supplementary Appendix). No patient discontinued treatment owing to an adverse event, had graft loss, or died.

In this trial of preemptive therapy in HCV-positive patients undergoing liver transplantation, a 4-week course of perioperative ledipasvir–sofosbuvir led to a high rate of sustained virologic response, suggesting that it may be an effective approach for preventing HCV recurrence. The only patient with a virologic relapse had NS5A resistance at baseline and had a response to an additional 12 weeks of therapy, suggesting that baseline resistance testing may guide the need for standard courses of therapy. This new perioperative approach needs to be tested in different populations, such as repeat or combined organ recipients and patients with previous DAA treatment failures, and in those with advanced renal failure (other DAAAs). In addition, there may be an opportunity to test modifications of this approach in liver or other solid organ recipients being offered HCV-positive organs as a way to increase the donor pool and number of transplants.

Figure 1. Hepatitis C Virus (HCV) RNA Levels from Day –1 to Post-Treatment Week 12.

The black curves represent the patients who had a sustained virologic response 12 weeks after the end of the 4-week treatment. The green curve represents a patient who had a relapse after initial treatment and had a sustained virologic response after 12 weeks of retreatment. The orange curve represents a patient who discontinued treatment on day 5 of the study owing to predefined stopping criteria. LLOQ denotes the lower limit of quantification.
Josh Levitsky, M.D.
Northwestern University
Chicago, IL
jlevitsk@nm.org

Elizabeth C. Verna, M.D.
Columbia University
New York, NY

Jacqueline G. O’Leary, M.D., M.P.H.
Baylor University
Dallas, TX

Natalie H. Bzowej, M.D.
Ochsner Clinical Foundation
New Orleans, LA

Dilip K. Moonka, M.D.
Henry Ford Hospital
Detroit, MI

Robert H. Hyland, D.Phil.
Sarah Arterburn, M.S.
Hadas Dvory-Sobol, Ph.D.
Diana M. Brainard, M.D.
John G. McHutchison, M.D.
Gilead Sciences
San Francisco, CA

Norah A. Terrault, M.D., M.P.H.
University of California, San Francisco
San Francisco, CA

Supported by Gilead Sciences.

Disclosures forms provided by the authors are available with the full text of this letter at NEJM.org.


DOI: 10.1056/NEJMc1611829

Correspondence Copyright © 2016 Massachusetts Medical Society.

INSTRUCTIONS FOR LETTERS TO THE EDITOR

Letters to the Editor are considered for publication, subject to editing and abridgment, provided they do not contain material that has been submitted or published elsewhere.

Letters accepted for publication will appear in print, on our website at NEJM.org, or both.

Please note the following:

• Letters in reference to a Journal article must not exceed 175 words (excluding references) and must be received within 3 weeks after publication of the article.

• Letters not related to a Journal article must not exceed 400 words.

• A letter can have no more than five references and one figure or table.

• A letter can be signed by no more than three authors.

• Financial associations or other possible conflicts of interest must be disclosed. Disclosures will be published with the letters. (For authors of Journal articles who are responding to letters, we will only publish new relevant relationships that have developed since publication of the article.)

• Include your full mailing address, telephone number, fax number, and e-mail address with your letter.

• All letters must be submitted at authors.NEJM.org.

Letters that do not adhere to these instructions will not be considered. We will notify you when we have made a decision about possible publication. Letters regarding a recent Journal article may be shared with the authors of that article. We are unable to provide prepublication proofs. Submission of a letter constitutes permission for the Massachusetts Medical Society, its licensees, and its assignees to use it in the Journal’s various print and electronic publications and in collections, revisions, and any other form or medium.

NOTICES

Notices submitted for publication should contain a mailing address and telephone number of a contact person or department. We regret that we are unable to publish all notices received.

15TH ANNUAL MILD COGNITIVE IMPAIRMENT SYMPOSIUM

The symposium, along with a workshop and public forum, will be held in Miami Beach, FL, Jan. 14 and 15. It is presented by the Wien Center for Alzheimer’s Disease and Memory Disorders, Mount Sinai Medical Center.

Contact MCI Symposium 2017, c/o World Events Forum, 1651 Whitcomb Ave., Des Plaines, IL 60018; or call (224) 938-9523; or e-mail meetings@worldeventsforum.com; or see http://www.mcismposium.org.

10TH INTERNATIONAL CONFERENCE ON ACUTE CARDIAC CARE

The conference will be held in Tel Aviv, Israel, Jan. 15–17.

Contact the Secretariat, 10th International Conference – ACC2017, P.O. Box 574, Jerusalem 91004, Israel; or call 972-2-6520574; or fax 972-2-6520558; or e-mail seminars@isas.co.il; or see http://www.acute-cardiac-care.com.

11TH ANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE

The conference will be held in San Diego, CA, Feb. 12–14. It is presented by the Alzheimer’s Drug Discovery Foundation.

Contact Sara Classen, Scientific Events, Alzheimer’s Drug Discovery Foundation, 57 W. 57th St., Suite 904, New York, NY 10019; or call (212) 901-8009; or fax (212) 901-8010; or e-mail sclassen@alzdiscovery.org; or see http://worldeventsforum.com/addf/drugdiscovery.